Next Article in Journal
Decasubstituted Pillar[5]arene Derivatives Containing L-Tryptophan and L-Phenylalanine Residues: Non-Covalent Binding and Release of Fluorescein from Nanoparticles
Previous Article in Journal
Fibrates Affect Levels of Phosphorylated p38 in Intestinal Cells in a Differentiation-Dependent Manner
Previous Article in Special Issue
Head and Neck Cancer Patients’ Survival According to HPV Status, miRNA Profiling, and Tumour Features—A Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 9
10.3390/ijms24097698
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer

by
Petra Anić
1,
Jasminka Golubić Talić
2,
Ksenija Božinović
3,
Emil Dediol
4,
Marinka Mravak-Stipetić
5,
Magdalena Grce
2 and
Nina Milutin Gašperov
2,*
1
Research Department, Srebrnjak Children’s Hospital, 10000 Zagreb, Croatia
2
Department of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia
3
Department of Molecular Biology, Ruđer Bošković Institute, 10000 Zagreb, Croatia
4
Department of Maxillofacial Surgery, Clinical Hospital Dubrava, 10000 Zagreb, Croatia
5
Department of Oral Medicine, School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(9), 7698; https://doi.org/10.3390/ijms24097698
Submission received: 13 March 2023 / Revised: 13 April 2023 / Accepted: 18 April 2023 / Published: 22 April 2023
(This article belongs to the Special Issue Human Papillomavirus and Head and Neck Cancer - Molecular Research)
Versions Notes

Abstract

:
The proportion of oral and oropharyngeal squamous cell carcinoma (OOSCC) that can be attributed to human papillomavirus (HPV) infection is growing nowadays. A potential factor indicating the occurrence of HPV-positive OSCC is a change in the degree of methylation of gene promoters that play a key role in the immune response. In this study, we investigated the difference in the methylation of EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12 gene promoters in samples of healthy oral mucosa versus samples of oral and oropharyngeal cancer. The presence of HPV infection in samples was examined earlier. To determine the difference in methylation of those gene promotors, isolated and bisulfite-modified DNA was analysed by the methylation-specific PCR method. The investigated gene promoters were found to be more hypomethylated in the oral and oropharyngeal cancer samples in comparison to normal tissue. The proportion of unmethylated gene promoters was similar in HPV-positive and HPV-negative cancers, although the data should be confirmed on a larger set of samples. To conclude, in samples of healthy oral mucosa, the investigated gene promoters were found to be methylated in a high percentage (73.3% to 100%), while in oral and oropharyngeal cancer samples, they were methylated in a low percentage (11.1% to 37%), regardless of HPV infection.

1. Introduction

Head and neck squamous cell carcinoma (HNSCC) is the 6th most frequent malignancy in the world, with over 650,000 new cases diagnosed each year [1]. Unfortunately, despite advances in treatment over the last years, there is still a relapse rate of 50% [2]. The most critical risk factor for HNSCC is excessive tobacco use, with or without alcohol consumption. Moreover, infection with high-risk (HR) types of human papillomavirus (HPV) is being investigated [3]. Because of the bad prognosis and very high mortality of patients, there is a strong need to find new biomarkers of this type of cancer.
Among HNSCC cases, cancer of the oral cavity is the most common, while oropharyngeal squamous cell carcinoma is most often associated with HPV [4], which is the reason for investigating these two types, oral and oropharyngeal squamous cell carcinoma (OOSCC), to a greater extent.
Changes in DNA methylation are possible factors associated with HNSCC, as well as OOSCC, development. DNA methylation, a chemical change that is not mediated by changes in the DNA sequence, is the most widely investigated epigenetic modification [5]. CpG dinucleotides are the target of approximately one-third of the transient changes that occur in human diseases and tumours. To date, the number of CpG sites has been significantly silenced in the mammalian genome by DNA methylation, leading to loss of their function, ultimately to adverse consequences [6].
The host immune system is an essential defence mechanism against tumour development via the coordinated and concerted activation of innate and adaptive immunity. The innate immune response is critical for virus removal [7]. On the other hand, genomic instability and other changes to DNA, including epigenetic ones, cause changes in gene expression and are a common feature of many cancers [8]. Changes in the methylation status of immune system gene promoters lead to a subsequent change in their expression and, thus, point to a possible role in the occurrence and the development of cancer.
Overall, the methylation of different genes, which act in independent pathways, was analysed in a variety of head and neck cancers. Many studies have shown that there are large variations in the choice of the best possible methylation biomarkers and their frequency of DNA methylation in these cancers [9,10]. Several studies have shown that DNA methylation is considered an early event in tumour development, and most investigations have focused on the discovery of biomarkers for early tumour detection [11,12]. Immune dysfunction in OOSCC involves many different phenotypic and functional changes in immune cells that occur with varying frequency in patients with early or late stages of the disease [13]. Hypomethylation in gene promoters normally leads to increased expression and production of proteins encoded by them, while hypermethylation in the same regions causes gene silencing. Hypomethylation in immune system gene promoters allows the production of proteins that have important roles in the defence of the host from foreign organisms, but also potentially in the defence against the development of various tumours, including OOSCC [14].
Current knowledge indicates that DNA methylation, as well as other epigenetic changes, significantly contribute to the appearance of certain types of head and neck cancer (HNC), suppressing or allowing the expression of specific genes that are important in the immune response of the organism itself. Our group conducted several studies on the altered methylation of immune system genes in HPV-related cancers and between a cluster of genes; we assumed that some of them could be validated as possible methylation biomarkers for OOSCC samples. Hence, in this study, we investigated the differences in the promoter methylation status of seven immune system genes, EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12, that could be promising as diagnostic and prognostic biomarkers, and thus in healthy oral mucosa versus oral and oropharyngeal cancers, in order to find out the most eligible biomarkers for those cancers.

2. Results

In this study, we investigated the methylation status of immune response gene promotors in 30 oral and oropharyngeal cancer samples and 30 controls (healthy oral mucosa). The subjects differed in age, tumour type, and HPV status. The mean age of the study population was 47 years: 60 years in the cancer patient group and 34 years in the control group. There were 23 oral and 7 oropharyngeal cancers. The HPV status was previously determined [15,16]. Briefly, there were 3 (13.0%) oral cavity cancers, 2 (28.6%) oropharyngeal cancers, and 1 (3.3%) control sample positive for HPV type 16. Three of the cancer samples had DNA inadequate for methylation analysis (two oral and one oropharyngeal cancer), and they were excluded from further analysis. Thus, we examined whether there was a difference in the methylation profiles of seven immune response gene promoters: EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12, between cancer samples and controls. Each tested gene showed some difference in promoter methylation between oral and oropharyngeal cancer tissues and healthy oral mucosal swabs.
Since primers that bind specifically to the unmethylated form of DNA were used in the MSP reaction, in all reactions for all tested genes, we obtained unmethylated control DNA that was positive, while methylated control DNA was negative.
None of the samples of the control group were unmethylated in the HLA DPB1 and IL12RB1 gene promoters, from which we can conclude that the methylation in these promoters was 100% of healthy oral mucosa samples. On the other hand, the majority (8/30; 26.7%) of the control samples were unmethylated in the HAVCR2 gene promoter. A total of 2 samples (6.7%) from this group had unmethylated GBP4 and MARCO gene promoters, while 4 samples (13.3%) were unmethylated in the EDARADD and SIGLEC12 gene promoters (Table 1).
Bisulfite conversion was successful in 27 (21 oral and 6 oropharyngeal cancers) OOSCC tested samples; for 3 samples, no result in MSP reactions was obtained with different primers for methylated (data not presented) or unmethylated forms of individual genes. Most of the oral and oropharyngeal cancer samples were unmethylated in almost all the investigated gene promoters: EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12. The percentage varied between 63% in the case of the HLA DPB1 gene and 88.9% for the EDARADD gene promoter (Table 1).
The majority of the healthy oral mucosa samples (29/30; 96.7%) were HPV-negative; thus, only 1 control sample was HPV-positive for HPV type 16 and was also methylated in all tested gene promoters (EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12). Among the HPV-negative samples, 11/29 (37.9%) were methylated in all the tested genes promoters. None of the samples of this group were unmethylated in the promoters of the HLA DPB1 and IL12RB1 gene promoters, from which we can conclude that the methylation in these promoters was obtained in 100% of the healthy oral mucosa HPV-negative or HPV-positive samples.
The methylation of the immune system gene promoters was studied in 27 samples of fresh OOSCC tissue, of which 21 were oral and 6 were oropharyngeal. Of the 27 analysed samples, 5 were HPV-positive; HPV positivity did not affect the gene promotors’ methylation profile. The proportion of HPV-positive cancers that were unmethylated in all tested gene promoters was 60% (3/5). In HPV-negative cancers, the proportion of unmethylated gene promotors was similar; 13 of 22 HPV-negative cancers were unmethylated in the promoters of all tested genes (59.1%). Spearman’s correlation also confirmed no association; the calculated Spearman’s rank correlation coefficient was 0.00719, with the significance level p = 0.9716.

3. Discussion

The main objective of this study was to determine the difference in the methylation status of the immune gene promoters EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12 in healthy oral mucosa versus oral and oropharyngeal squamous cell carcinoma (OOSCC) tissue. Of the investigated immune system genes, the methylation of the HLA class II genes has been studied the most. It has been shown that change in the methylation of HLA DPB1 (Major Histocompatibility Complex, class II, DP Beta 1) contributes to the development of multiple sclerosis, a disease of the central nervous system [17]. Herein, the HLA DPB1 gene promoter was found to be significantly hypomethylated in cancer tissue (63%) in comparison to healthy oral mucosa tissue (0%). Several studies suggest that DNA methylation in the HLA class II gene region may mediate genetic susceptibility to immune-mediated diseases, such as rheumatoid arthritis [18], type 1 diabetes, and food allergies [19]. The methylation of the MARCO gene (Macrophage Receptor with Collagenous Structure) has also been investigated in tolerant macrophages. Macrophage tolerance can be induced by a variety of toxic signals, which activate various receptors and signalling pathways. DNA methylation in combination with histone modification is thought to play a role in regulating MARCO gene expression. Accordingly, the inhibition with H3K4me3 in the MARCO promoter region was significantly reduced after treatment with a demethylating agent [20]. In this study, we found that MARCO gene promoter was significantly hypomethylated in cancer tissue (85.2%) in comparison to healthy oral mucosa (6.7%). Studies have shown that hypermethylation of the IL12RB (Interleukin 12 Receptor Subunit Beta) genes can lead to the reduction of tuberculosis-specific production of the cytokine interferon gamma (IFNγ) [21]. Otherwise, IFNγ expression has an important role in the innate and acquired immune response due to the activation of macrophages and the formation of MHC complexes [22]. We found that IL12RB1 gene promoter was significantly hypomethylated in cancer tissue (85.2%) in comparison to healthy oral mucosa (0%). In addition, further research is needed to determine whether methylation is an indicator of age itself or if it is functionally related to aging. However, the gene whose methylation is studied with regard to aging is the EDARADD (Ectodysplasin A Receptor Associated Adapter Protein) gene, whose previously detected methylation in CpG sites was negatively correlated with age, being hypomethylated in older age [23]. We found that EDARADD was significantly hypomethylated in cancer tissues (88.9%) in comparison to normal oral mucosa (13.3%), which is in line with age-dependent findings, since the cancer group age (average 60 years) was much higher than that of the normal oral samples. In another study, the hypomethylation of the EDARADD promoter was associated with a shorter survival in non-small cell lung cancer compared to those patients who showed higher levels of promoter methylation, and this serves as a biomarker of this disease [24]. A differently methylated region was found in the region of the 5′UTR of the GBP1 gene (Interferon-induced Guanylate-Binding Protein 1), which was hypomethylated in triple-negative breast cancer samples compared to normal samples [25], which is similar to our findings in oral and oropharyngeal cancers. Furthermore, overexpression of HAVCR (Hepatitis A Virus Cellular Receptor) due to hypomethylation of the gene promoter may be a diagnostic biomarker for colorectal cancer and a prognostic marker for a longer disease-free interval after colorectal cancer surgery [26]. The HAVCR1 protein is also a useful biomarker for diagnosing renal cell carcinoma and ovarian clear-cell carcinoma [27]. We found that HAVCR2 gene promoter was hypomethylated in 77.8% of oral and oropharyngeal cancers. The SIGLEC12 gene (Sialic acid-binding Immunoglobulin-type Lectin 12) is related to the innate immune system and class I MHC-mediated antigen processing and presentation. We found here that SIGLEC12 gene promoter was significantly hypomethylated in cancer tissues (85.2%), in comparison to normal oral mucosa (13.3%). Interestingly, the immune system genes were also statistically significantly hypomethylated in cervical cancer (CC) samples compared to normal tissue, and all of the genes analysed in this study belong to the regulatory genes of the immune system [28].
It is known from the literature that there is an association between the hypomethylation of the immune system gene promoters and the presence of HPV. Previous gene expression studies on CC and HNC tissue samples revealed that a number of immune-related genes are dysregulated in HPV-positive cancers compared to normal tissues and HPV-negative cancers [29,30]. Determination of the HPV direct embodiment was recently performed [29,31]. The two most regulated groups of genes were involved in immune regulation and extracellular matrix organization. Subsequently, many of these immune genes were specifically regulated by the HPV type 16 oncoprotein E7, which was desirable to suppress anti-tumour immune responses [31]. Namely, it has been shown that immune system genes are significantly hypomethylated in CC compared to normal tissue, suggesting that immune system activation is most likely a response to HPV oncogenes E6 and E7, which are markedly expressed in advanced cancer [32]. Furthermore, other studies have shown that regulation of host DNA methylation by HPV type 16 E7 is associated with suppression of the host immune system during HPV-associated tumour progression [29]. Interestingly, a recent clinical trial showed that treatment with DNA methylation inhibitors suppressed the growth of HPV-positive HNCs. Significantly, HPV-positive HNCs were more sensitive to treatment with the DNA-demethylating agent 5-aza-2′-deoxycytidine than HPV-negative HNCs [33]. These findings suggest that HPV-induced DNA methylation dysregulation can be reversed by demethylating agents as targeted therapies for tumours associated with HPV infection. Several studies have shown that the presence of HPV DNA is a favourable prognostic factor with respect to relapse and survival [34,35]. In contrast, other studies have shown that patients with positivity to high-risk HPV had a poorer prognosis [36,37] or did not show a significant association between HR HPV infection and clinical outcomes [38,39]. In 2009, Williams et al. investigated whether HPV-specific immune mechanisms could result in tumour removal. For this purpose, they examined immunocompetent and immunologically incompetent mice with or without HPV. In the immunocompetent group, one-third of the HPV-positive mice cleared their tumours compared to the HPV-negative mice. Moreover, the HPV-positive mice had significantly longer survival than the HPV-negative mice [40].

4. Material and Methods

4.1. Study Group

Healthy oral mucosa samples were collected with a cytobrush from healthy subjects in the School of Dental Medicine, University of Zagreb, Croatia, during regular examinations. Oral cavity and oropharyngeal cancer tissue was collected at the Clinical Hospital Dubrava, Zagreb. The overall study group comprised 60 samples: 30 samples of healthy oral mucosa and 30 OOSCC samples, of which 23 were oral cavity cancers and 7 oropharyngeal cancers. The median age of the control healthy group was 34, while that of the cancer patients was 60. There were 6 (20%) smokers in the healthy group and 23 (76.7%) smokers in the OOSCC samples group. The samples collection was regulated through laboratory service request forms that were signed and approved by the patient and the clinician. The samples were previously tested for mucosal HPV presence, as described earlier [15,16]. Overall, 3 oral cavity cancers (13.0%), 2 oropharyngeal cancers (28.6%), and 1 control sample (3.3%) were positive for HPV (genotype 16).

4.2. DNA Preparation

DNA from healthy oral mucosa and OOSCC samples was isolated on BioRobot EZ1 (Qiagen) according to the manufacturer’s instructions. Extracted DNA was dissolved in 50–100 μL of tri-distillate sterile water and then stored at −20 °C. The quality of the samples was evaluated with a NanoPhotometer (Implen, Westlake Village, CA, USA), and those with the ratio A260/280 between 1.7 and 1.9 were included in the study [41].

4.3. Bisulfite Conversion

DNA from the OOSCC samples was modified with sodium bisulfite using an EpiTect Bisulfite Kit (Qiagen, Germantown, MD, USA) and purified according to the manufacturer’s instructions. Briefly, after bisulfite treatment, all unmethylated cytosines were converted to uracil, while methylated cytosines remain unchanged.

4.4. Genes and Primers Design

Promoters of 7 genes were selected for investigation: EDARADD (Gene ID: 128178), GBP4 (Gene ID: 115361), HAVCR2 (Gene ID: 84868), HLA DPB1 (Gene ID: 3115), IL12RB1 (Gene ID: 3594), MARCO (Gene ID: 8685), and SIGLEC12 (Gene ID: 89858).
The primers’ sequences for unmethylated gene forms were designed with the MethPrimer program for designing bisulfite-conversion-based Methylation PCR Primers in the The Li Lab, Peking Union Medical College Hospital (PUMCH, Beijing, China), Chinese Academy of Medical Sciences.
The primers’ sequences for the bisulfite-converted gene promoters are presented in Table 2.

4.5. Methylation Analysis by MSP

The gene promoter methylation status was obtained by the Methylation Specific Polymerase Chain Reaction (MSP) with primers specific for unmethylated forms of 7 gene promoters—EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12—in healthy oral mucosa versus oral and oropharyngeal cancers. Two commercially available whole human genome DNA previously treated with sodium bisulfite (Qiagen, USA) were used as controls: one completely unmethylated (EpiTect Control DNA, unmethylated; Qiagen, USA) and one completely methylated (EpiTect Control DNA, methylated; Qiagen, USA).
MSP was performed for each primer set separately in a 20 µL volume containing 0.4 mM of each dNTP, 1 µM of each primer, 4 mM MgCl2, 5× Green GoTaq Flexi buffer, H2O, 0.08 µL GoTaq Hot Start Polymerase (Promega, Madison, WI, USA), and bisulfite-converted DNA in a final concentration of 25 ng/µL. All components of the reaction were added in equal volumes, except for the primers and the water, which were added depending on which gene was involved. Methylated and unmethylated control DNA was used in a final concentration of 25 ng/µL. Aliquots of MSP products were analysed on a 2% agarose gel. Briefly, the MSP reaction itself was carried out according to the following conditions: 5 min denaturation at 95 °C was followed by 40 to 45 cycles of denaturation at 95 °C for 30 s, annealing at 56–64 °C for 30 s, elongation at 72 °C for 50 s, and the final 7 min extension at 72 °C.
The annealing temperature varied with different primers: 62 °C for HAVCR2 (U, Unmethylated primers), 63 °C for EDARADD (U) and GBP4 (U), 61 °C for SIGLEC12 (U) and HLA DPB1 (U). At the lowest temperature of 56 °C were bound primers for the IL12RB1 gene, while at the highest temperature of 64 °C were bound primers for the MARCO gene. The number of repeat cycles varied with different primers: 45 for EDARADD (U) and 40 for the GBP4 (U), HAVCR2 (U), HLA DPB1 (U), IL12RB1 (U), MARCO (U), and SIGLEC12 (U) gene primers.

4.6. Statistical Methods

The standard Chi-square (χ2) test was used for the comparison of two groups of samples (normal vs. cancer) for each gene promoter.
Spearman’s correlation was used, and the Spearman’s rank correlation coefficient between groups’ data (HPV positivity and gene promoter methylation) was calculated.

5. Conclusions

In the samples of healthy oral mucosa investigated in this study, it was shown that promoters of genes that have a function in the immune system, such as the EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12 genes, are methylated in a high percentage (73.3% to 100%). In OOSCC samples with a different HPV status, it was shown that promoters of the same genes are methylated in a low percentage (11.1% to 37%). However, no correlation with the HPV positivity and the hypomethylation of immune system genes was found. Recently, we have just begun to understand the role of normal DNA methylation in the development and function of the immune system and the role that altered DNA methylation plays in pathological conditions. The demethylation of immune system gene promoters could explain why certain individuals with HNCs have a better prognosis, while others do not. The poorer prognosis of these cancers must almost certainly be related to the fact that these cancers strongly affect the host immune system, and this fact could be important for the development of new therapeutic or prophylactic anticancer approaches.

Author Contributions

Conceptualization, N.M.G.; Data curation, E.D. and M.M.-S.; Formal analysis, P.A. and J.G.T.; Funding acquisition, M.G. and N.M.G.; Methodology, K.B. and N.M.G.; Resources, E.D. and M.M.-S.; Supervision, N.M.G.; Validation, N.M.G.; Writing—original draft, P.A.; Writing—review & editing, M.G. and N.M.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Croatian Science Foundation (IP-2013-11-4758) and the European Social Fund (HR.3.2.01.-0086).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Verbal or written patient/participant consent was obtained for each specimen that was collected for research purposes. The relevant patient data (age, diagnosis, HPV detection result) and the extracted DNA were further encoded and processed anonymously in the laboratory. The study was approved by the Institutional Ethical Board of the Ruđer Bošković Institute (BEP-3748/2-2014); the Ethical Board of the School of Dental Medicine, University of Zagreb (EP-SFZG-10/06-2014); and the Ethical Board of the Clinical Hospital Dubrava (EP-KBD-10/06/-2014). The study was conducted in accordance with the Declaration of Helsinki of 1975 (DoH/Oct2008).

Data Availability Statement

All data are available in the submitted form or upon request.

Acknowledgments

The authors are grateful to Ivan Sabol for data processing and statistical analyses.

Conflicts of Interest

The authors report no conflict of interest.

References

  1. WHO. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr/Default.aspx (accessed on 21 June 2012).
  2. Glorieux, M.; Dok, R.; Nuyts, S. Novel DNA targeted therapies for head and neck cancers: Clinical potential and biomarkers. Oncotarget 2017, 8, 81662–81678. [Google Scholar] [CrossRef] [PubMed]
  3. Arantes, L.M.P.B.; de Carvalho, A.C.; Melendez, M.E.; Carvalho, A.L. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev. Mol. Diagn. 2017, 18, 85–112. [Google Scholar] [CrossRef] [PubMed]
  4. De Martel, C.; Plummer, M.; Vignat, J.; Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017, 141, 664–670. [Google Scholar] [CrossRef] [PubMed]
  5. Zhou, C.; Ye, M.; Ni, S.; Li, Q.; Ye, D.; Li, J.; Shen, Z.; Deng, H. DNA methylation biomarkers for head and neck squamous cell carcinoma. Epigenetics 2018, 13, 398–409. [Google Scholar] [CrossRef] [PubMed]
  6. Yoder, J.A.; Walsh, C.P.; Bestor, T.H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997, 13, 335–340. [Google Scholar] [CrossRef] [PubMed]
  7. Hibma, M.H. The immune response to papillomavirus during infection persistence and regression. Open Virol. J. 2012, 6, 241–248. [Google Scholar] [CrossRef] [PubMed]
  8. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef]
  9. Sanchez-Cespedes, M.; Esteller, M.; Wu, L.; Nawroz-Danish, H.; Yoo, G.H.; Koch, W.M.; Jen, J.; Herman, J.G.; Sidransky, D. Gene Promoter Hypermethylation in Tumors and Serum of Head and Neck Cancer Patients. Cancer Res. 2000, 60, 892–895. [Google Scholar]
  10. Demokan, S.; Suoglu, Y.; Demir, D.; Gozeler, M.; Dalay, N. Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. Ann. Oncol. 2006, 17, 995–999. [Google Scholar] [CrossRef]
  11. Sasidharan, N.V.; Toor, S.M.; Taha, R.Z.; Shaath, H.; Elkord, E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin. Epigenet. 2018, 10, 104. [Google Scholar] [CrossRef]
  12. Pan, Y.; Liu, G.; Zhou, F.; Su, B.; Li, Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin. Exp. Med. 2018, 18, 1–14. [Google Scholar] [CrossRef] [PubMed]
  13. Reichert, E.T.; Strauss, L.; Wagner, E.M.; Gooding, W.; Whiteside, T.L. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 2002, 8, 3137–3145. [Google Scholar] [PubMed]
  14. Baylin, S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2 (Suppl. S1), S4–S11. [Google Scholar] [CrossRef]
  15. Milutin-Gasperov, N.; Sabol, I.; Halec, G.; Matovina, M.; Grce, M. Retrospective study of the prevalence of high-risk human papillomaviruses among Croatian women. Coll. Antropol. 2007, 31 (Suppl. S2), 89–96. [Google Scholar] [PubMed]
  16. Milutin, G.N.; Sabol, I.; Planinić, P.; Grubišić, G.; Fistonić, I.; Ćorušić, A.; Grce, A. Methylated Host Cell Gene Promoters and Human Papillomavirus Type 16 and 18 Predicting Cervical Lesions and Cancer. PLoS ONE 2015, 10, e0129452. [Google Scholar]
  17. Kular, L.; Liu, Y.; Ruhrmann, S.; Zheleznyakova, G.; Marabita, F.; Gomez-Cabrero, D.; James, T.; Ewing, E.; Lindén, M.; Górnikiewicz, B.; et al. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nat. Commun. 2018, 9, 1–15. [Google Scholar] [CrossRef]
  18. Liu, Y.; Aryee, M.J.; Padyukov, L.; Fallin, M.D.; Hesselberg, E.; Runarsson, A.; Reinius, L.; Acevedo, N.; Taub, M.; Ronninger, M.; et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 2013, 31, 142–147. [Google Scholar] [CrossRef]
  19. Hong, X.; Hao, K.; Ladd-Acosta, C.; Hansen, K.D.; Tsai, H.-J.; Liu, X.; Xu, X.; Thornton, T.A.; Caruso, D.; Keet, C.A.; et al. Genome-wide association study identifies peanut allergy-specific loci and evidence of epigenetic mediation in US children. Nat. Commun. 2015, 6, 6304. [Google Scholar] [CrossRef]
  20. Jing, J.; Yang, I.V.; Hui, L.; Patel, J.A.; Evans, C.M.; Prikeris, R.; Kobzik, L.; O’Connor, B.P.; Schwartz, D.A. Role of macrophage receptor with collagenous structure in innate immune tolerance. J. Immunol. 2013, 190, 6360–6367. [Google Scholar] [CrossRef]
  21. DiNardo, A.R.; Nishiguchi, T.; Mace, E.M.; Rajapakshe, K.; Mtetwa, G.; Kay, A.; Maphalala, G.; Secor, W.E.; Mejia, R.; Orange, J.S.; et al. Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes. J. Immunol. 2018, 201, 124–133. [Google Scholar] [CrossRef]
  22. Schoenborn, J.R.; Wilson, C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 2007, 96, 41–101. [Google Scholar]
  23. Dias, H.C.; Cordeiro, C.; Real, F.C.; Cunha, E.; Manco, L. Age Estimation Based on DNA Methylation Using Blood Samples From Deceased Individuals. J. Forensic Sci. 2019, 65, 465–470. [Google Scholar] [CrossRef]
  24. Vizoso, M.; Puig, M.; Carmona, F.; Maqueda, M.; Velásquez, A.; Gomez, A.; Labernadie, A.; Lugo, R.; Gabasa, M.; Rigat-Brugarolas, L.G.; et al. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis 2015, 36, 1453–1463. [Google Scholar] [CrossRef]
  25. Quintero, M.; Adamoski, D.; Reis, L.M.D.; Ascenção, C.F.R.; Oliveira, K.R.S.; de Gonçalves, K.; Dias, M.M.; Carazzolle, M.F.; Dias, S.M.G. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC Cancer 2017, 17, 727. [Google Scholar] [CrossRef] [PubMed]
  26. Wang, K.; Ling, T.; Wu, H.; Zhang, J. Screening of candidate tumor-suppressor genes in 3p21.3 and investigation of the methylation of gene promoters in oral squamous cell carcinoma. Oncol. Rep. 2013, 29, 1175–1182. [Google Scholar] [CrossRef]
  27. Lin, F.; Zhang, P.L.; Yang, X.J.; Shi, J.; Blasick, T.; Han, W.K.; Wang, H.L.; Shen, S.S.; Teh, B.T.; Bonventre, J.V. Human kidney injury molecule-1 (hKIM-1): A useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am. J. Surg. Pathol. 2007, 31, 371–381. [Google Scholar] [CrossRef]
  28. Milutin, G.N.; Farkas, S.A.; Nilsson, T.K.; Grce, M. Epigenetic activation of immune genes in cervical cancer. Immunol. Lett. 2014, 162, 256–257. [Google Scholar] [CrossRef] [PubMed]
  29. Cicchini, L.; Westrich, J.A.; Xu, T.; Vermeer, D.W.; Berger, J.N.; Clambey, E.T.; Lee, D.; Song, J.I.; Lambert, P.F.; Greer, R.O.; et al. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14. Mbio 2016, 7, e00270-16. [Google Scholar] [CrossRef]
  30. Pyeon, D.; Newton, M.A.; Lambert, P.F.; Boon, J.A.D.; Sengupta, S.; Marsit, C.J.; Woodworth, C.D.; Connor, J.P.; Haugen, T.H.; Smith, E.M.; et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007, 67, 4605–4619. [Google Scholar] [CrossRef] [PubMed]
  31. Cicchini, L.; Blumhagen, R.Z.; Westrich, J.A.; Myers, M.E.; Warren, C.J.; Siska, C.; Raben, D.; Kechris, K.J.; Pyeon, D. High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes. Sci. Rep. 2017, 7, 3633. [Google Scholar] [CrossRef]
  32. Iarc, W. Handbooks of Cancer Prevention Volume 10: Cervix Cancer Screening; IARC Press: Lyon, France, 2005. [Google Scholar]
  33. Biktasova, A.; Hajek, M.; Sewell, A.; Gary, C.; Bellinger, G.; Deshpande, H.A.; Bhatia, A.; Burtness, B.; Judson, B.; Mehra, S.; et al. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clin. Cancer Res. 2017, 23, 7276–7287. [Google Scholar] [CrossRef] [PubMed]
  34. Lindel, K.; Beer, K.T.; Laissue, J.; Greiner, R.H.; Aebersold, D.M. Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer 2001, 92, 805–813. [Google Scholar] [CrossRef] [PubMed]
  35. Lindquist, D.; Romanitan, M.; Hammarstedt-Nordenvall, L.; Näsman, A.; Dahlstrand, H.; Lindholm, J.; Onelöv, L.; Ramqvist, T.; Ye, W.; Munck-Wikland, E.; et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol. Oncol. 2007, 1, 350–355. [Google Scholar] [CrossRef] [PubMed]
  36. Hansson, B.G.; Rosenquist, K.; Antonsson, A.; Wennerberg, J.; Schildt, E.-B.; Bladström, A.; Gunilla, A. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in southern Sweden. Acta Otolaryngol. 2005, 125, 1337–1344. [Google Scholar] [CrossRef]
  37. Rosenquist, K. Risk factors in oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in southern Sweden. Swed. Dent. J. Suppl. 2005, 179, 1–66. [Google Scholar]
  38. Morshed, K. Association between human papillomavirus infection and laryngeal squamous cell carcinoma. J. Med. Virol. 2010, 82, 1017–1023. [Google Scholar] [CrossRef]
  39. Ozdayi, G.; Kemaloglu, Y.; Ekinci, O.; Dogan, B.; Ilhan, M.N.; Aydil, U.; Akyol, G.; Koybasioglu, A.; Inal, E.; Rota, S. Role of human papillomavirus in the clinical and histopathologic features of laryngeal and hypopharyngeal cancers. J. Otolaryngol. Head Neck Surg. 2009, 38, 119–125. [Google Scholar]
  40. Williams, R.; Lee, D.W.; Elzey, B.D.; Anderson, M.E.; Hostager, B.S.; Lee, J.H. Preclinical models of HPV+ and HPV- HNSCC in mice: An immune clearance of HPV+ HNSCC. Head Neck 2009, 31, 911–918. [Google Scholar] [CrossRef] [PubMed]
  41. Manos, M.M.; Ting, Y.; Wright, D.K.; Levwis, A.J.; Broker, T.R.; Wolinsky, S.M. The use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989, 7, 209–214. [Google Scholar]
Table
Table 1. Unmethylated immune system gene promoters in healthy oral mucosa and oral/oropharyngeal cancer samples.
Table 1. Unmethylated immune system gene promoters in healthy oral mucosa and oral/oropharyngeal cancer samples.
Immune System Gene PromotersNo. of
Unmethylated Control Samples * (%)		No. of
Unmethylated Cancer Samples ** (%)		p-Value
EDARADD4 (13.3)24 (88.9)p < 0.0001
GBP42 (6.7)23 (85.2)p < 0.0001
HAVCR28 (26.7)21 (77.8)p = 0.0001
HLA DPB10 (0.0)17 (63)p < 0.0001
IL12RB10 (0.0)23 (85.2)p < 0.0001
MARCO2 (6.7)23 (85.2)p < 0.0001
SIGLEC124 (13.3)23 (85.2)p < 0.0001
* 30 healthy oral mucosa, ** 21 oral and 6 oropharyngeal cancers.
Table
Table 2. Primers and primers’ sequences used in the study.
Table 2. Primers and primers’ sequences used in the study.
PrimerSequence 5′-3′
EDARADD-UfTTGTTTTGGAATAGTTAGAGGATGG
EDARADD-UrAAATACCTAAAAAAATCTCCACACT
GBP4-UfTGTGTTTGTAGTTTTAGTTATATGG
GBP4-UrTAAAACAAAATTTCACTCTATCACC
HAVCR2-UfGGTAGGAGTTTTTAGGGAAAAATG
HAVCR2-UrAAACAACAAAATTTATATCCCCATC
HLA DPB1-UfGGAAGGTATAGTTTGATTTTGTTTG
HLA DPB1-UrAAACCCTATTTATACAAATCCTCATT
IL12RB1-UfTTAGTTTGGGTTTAGAGTATGATGT
IL12RB1-UrCAAAATAAACTTCTCAAAATACACA
MARCO-UfATTTAGTGTTTGTTAGGATTGTTGG
MARCO-UrTAACATCAAAATTTTACCACTCATC
SIGLEC12-UfTTGATAATGTAGAAGTTTGTGATGG
SIGLEC12-UrACCAATAACCATAAACTAAATCAAA
Uf = unmethylated forward primer; Ur = unmethylated reverse primer.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Anić, P.; Golubić Talić, J.; Božinović, K.; Dediol, E.; Mravak-Stipetić, M.; Grce, M.; Milutin Gašperov, N. Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer. Int. J. Mol. Sci. 2023, 24, 7698. https://doi.org/10.3390/ijms24097698

AMA Style

Anić P, Golubić Talić J, Božinović K, Dediol E, Mravak-Stipetić M, Grce M, Milutin Gašperov N. Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer. International Journal of Molecular Sciences. 2023; 24(9):7698. https://doi.org/10.3390/ijms24097698

Chicago/Turabian Style

Anić, Petra, Jasminka Golubić Talić, Ksenija Božinović, Emil Dediol, Marinka Mravak-Stipetić, Magdalena Grce, and Nina Milutin Gašperov. 2023. "Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer" International Journal of Molecular Sciences 24, no. 9: 7698. https://doi.org/10.3390/ijms24097698

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop